Synaptic Pharmaceutical Corporation

H. Lundbeck A/s

Eli Lilly and Company

Neurogenetic Corporation

Synaptic Pharmaceutical Coorporation

Theresa A Branchek

Richard L Weinshank

Paul R Hartig

Mary W Walker

Jonathan A Bard

Carlos C Forray

Christophe P G Gerald

Kelli E Smith

Christophe P Gerald

Charles Gluchowski

George Chiu

John M Wetzel

David Linemeyer

Kenneth A Jones

Beth E Borowsky

Hung-Teh Kao

Laurence A Borden

James E Audia

Marlene L Cohen

Kirk Willis Johnson

Lee A Phebus

Douglas A Craig

Joseph Tamm

This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Uses of galanin GALR2 receptors

This invention provides isolated nucleic acids encoding chimeric G proteins, vectors comprising nucleic acids encoding chimeric G proteins, cells comprising such vectors, processes of determining agonists and antagonists of mammalian G protein-coupled receptors utilizing chimeric G proteins, processes of determining compounds which bind to mammalian G protein-coupled receptors utilizing chimeric G proteins, processes for making a composition of matter which specifically binds to a mammalian G protein-coupled receptor utilizing chimeric G proteins, processes for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by a process of the invention utilizing chimeric G proteins, processes of identifying a ligand for a mammalian G protein-coupled receptor utilizing chimeric G proteins, and processes of screening a plurality of independent clones to identify and isolate a clone encoding a mammalian G protein-coupled receptor utilizing chimeric G proteins.

Chimeric G proteins and uses thereof

Method of preparing GALR2 receptors composition

This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Method of using cells expressing galanin receptor 3 (GALR3)

This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA encoding a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.

Method of obtaining compositions comprising Y4 specific compounds

This invention provides isolated nucleic acid molecules encoding a neuropeptide Y (NPY) Y5 receptor which hybridizes under high stringency conditions to a nucleic acid molecule of SEQ ID NO:3, vectors comprising such isolated nucleic acid molecules, and cells comprising such vectors.

Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

DNA encoding galanin GALR2 receptors

The invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has structure (I). In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.

Methods of modifying feeding behavior using compounds with afinity for the human hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; adrenergic receptor, a human &agr; adrenergic receptor, and a human histamine H receptor, and, binds to a human &agr; adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; adrenergic receptor. Compounds meeting these criteria are provided.

Use of &agr;1C specific compounds to treat benign prostatic hyperplasia

Method of identifying compounds that bind galanin receptor (GALR2)

This invention provides isolated nucleic acid molecules encoding human 5-HT receptors, isolated proteins which are human 5-HT receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT receptors, mammalian cells comprising such vectors, antibodies directed to human 5-HT receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT receptor, pharmaceutical compounds related to human 5-HT receptors, and nonhuman transgenic animals which express DNA which encodes a normal or a mutant human 5-HT receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT receptor.

Method of obtaining a composition comprising a 5-HT1D selective compound

This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT receptor and an isolated nucleic acid molecule encoding a human 5-HT receptor, an isolated protein which is a mammalian 5-HT receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT receptor, pharmaceutical compounds related to the human 5-HT receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT receptor.

Method of obtaining compositions

This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.

Method of obtaining compositions comprising Y2 specific compounds

This invention provides an isolated nucleic acid molecule encoding a human 5-HT receptor, an isolated protein which is a human 5-HT receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT receptor, pharmaceutical compounds related to human 5-HT receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT receptor.

Growing community of inventors

Teaneck, NJ, United States of America

Theresa A Branchek